Continuous anti-angiogenic therapy after tumor progression in patients with recurrent high-grade epithelial ovarian cancer: phase I trial experience.
Continuous anti-angiogenic therapy after tumor progression in patients with recurrent high-grade epithelial ovarian cancer: phase I trial experience.
复制标题
复发性高级别上皮性卵巢癌患者肿瘤进展后持续抗血管生成治疗：I 期试验经验
DOI：
10.18632/oncotarget.9048
复制
发表时间：
2016-06-07
期刊：
影响因子：
--
通讯作者：
Fu S
中科院分区：
文献类型：
--
作者：
Hou MM;Wang Z;Janku F;Piha-Paul S;Naing A;Hong D;Westin S;Coleman RL;Sood AK;Tsimberidou AM;Subbiah V;Wheler J;Zinner R;Lu K;Meric-Bernstam F;Fu S
高级别上皮性卵巢癌 (HG-EOC) 是全球最致命的妇科恶性肿瘤。一旦患者出现化疗耐药性，就需要有效的新策略来改善预后。我们分析了参加德克萨斯大学 MD 安德森癌症中心 94 项 I 期临床试验的连续 242 名 HG-EOC 患者的特征和结果。基线乳酸脱氢酶水平、白蛋白水平和转移部位数量是总生存期 (OS) 的独立预测因素。接受超过 1 个 I 期方案与 OS 改善相关 (p < 0.001)。包括化疗药物加贝伐单抗或 Aurora A 激酶抑制剂的治疗方案使中位无进展生存期 (PFS) 持续时间超过 6 个月。尽管在 I 期临床试验中接受基于贝伐单抗方案的患者的 PFS 显着长于接受其他抗血管生成治疗的患者 (p = 0.017)，但接受血管内皮生长因子受体酪氨酸激酶抑制剂 (VEGFR-TKI) 治疗的患者的 OS (12.2 个月) 显着长于未接受 VEGFR-TKI 治疗的患者 (8.6 个月，p = 0.015)。总之，抗血管生成治疗是治疗 HG-EOC 最重要的策略之一，即使对于那些已经经历肿瘤进展的患者也是如此。因此，应鼓励符合条件的 HG-EOC 患者参与抗血管生成疗法的新 I 期研究，即使在疾病进展后也是如此。
High-grade epithelial ovarian cancer (HG-EOC) is the most lethal gynecologic malignancy worldwide Once patients develop chemoresistance, effective novel strategies are required to improve prognosis We analyzed characteristics and outcomes of 242 consecutive patients with HG-EOC participating in 94 phase I clinical trials at The University of Texas MD Anderson Cancer Center. Baseline lactate dehydrogenase levels, albumin levels, and number of metastatic sites were independent predictors of overall survival (OS). Receiving more than 1 phase I protocol was associated with improved OS (p < 0.001). Regimens including a chemotherapeutic agent plus bevacizumab or Aurora A kinase inhibitor led to a median progression-free survival (PFS) duration of more than 6 months. Although patients receiving bevacizumab-based regimens in the phase I clinical trials had significantly longer PFS than those receiving other anti-angiogenic therapies (p = 0.017), patients treated with vascular endothelial growth factor receptor-tyrosine kinase inhibitors (VEGFR-TKIs) had significantly longer OS (12.2 months) than those not treated with VEGFR-TKIs (8.6 months, p = 0.015). In conclusion, anti-angiogenic therapy is one of the most important strategies for the treatment of HG-EOC, even in those who have already experienced tumor progression. Therefore, eligible patients with HG-EOC should be encouraged to participate in novel phase I studies of anti-angiogenic therapies, even after disease progression.
登录
查看更多内容
DOI：
10.1038/nrclinonc.2013.5
发表时间：
2013-04
期刊：
Nature reviews. Clinical oncology
影响因子：
--
作者：
通讯作者：
--
影响因子：
8.4
作者：
Eisenhauer, E. A.;Therasse, P.;Verweij, J.
通讯作者：
Verweij, J.
影响因子：
4.7
作者：
Fu S;Hennessy BT;Ng CS;Ju Z;Coombes KR;Wolf JK;Sood AK;Levenback CF;Coleman RL;Kavanagh JJ;Gershenson DM;Markman M;Dice K;Howard A;Li J;Li Y;Stemke-Hale K;Dyer M;Atkinson E;Jackson E;Kundra V;Kurzrock R;Bast RC Jr;Mills GB
通讯作者：
Mills GB
DOI：
10.1158/1078-0432.ccr-10-3176
发表时间：
2011-08-15
期刊：
Clinical cancer research : an official journal of the American Association for Cancer Research
影响因子：
--
作者：
Matsuo K;Nishimura M;Bottsford-Miller JN;Huang J;Komurov K;Armaiz-Pena GN;Shahzad MM;Stone RL;Roh JW;Sanguino AM;Lu C;Im DD;Rosenshien NB;Sakakibara A;Nagano T;Yamasaki M;Enomoto T;Kimura T;Ram PT;Schmeler KM;Gallick GE;Wong KK;Frumovitz M;Sood AK
通讯作者：
Sood AK
影响因子：
--
作者：
Hou MM;Liu X;Wheler J;Naing A;Hong D;Coleman RL;Tsimberidou A;Janku F;Zinner R;Lu K;Kurzrock R;Fu S
通讯作者：
Fu S